{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:35:55Z","timestamp":1777426555776,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00108-017-0332-y","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T04:40:54Z","timestamp":1507178454000},"page":"1142-1149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pseudomonas-aeruginosa-Infektion bei chronisch obstruktiver Lungenerkrankung","Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease"],"prefix":"10.1007","volume":"58","author":[{"given":"G. G. U.","family":"Rohde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"332_CR1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm.2017.04.20","volume":"5","author":"E Monso","year":"2017","unstructured":"Monso E (2017) Microbiome in chronic obstructive pulmonary disease. Ann Transl Med 5:251","journal-title":"Ann Transl Med"},{"issue":"8","key":"332_CR2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1164\/rccm.200709-1413OC","volume":"177","author":"TF Murphy","year":"2008","unstructured":"Murphy TF, Brauer AL, Eschberger K et\u00a0al (2008) Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177(8):853\u2013860","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"332_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2466-14-103","volume":"14","author":"M Gallego","year":"2014","unstructured":"Gallego M, Pomares X, Espasa M et\u00a0al (2014) Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med 14:103","journal-title":"BMC Pulm Med"},{"key":"332_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1513\/AnnalsATS.201310-350OC","volume":"11","author":"H Desai","year":"2014","unstructured":"Desai H, Eschberger K, Wrona C et\u00a0al (2014) Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 11:303\u2013309","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"332_CR5","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/IAI.01904-05","volume":"74","author":"MM Fernaays","year":"2006","unstructured":"Fernaays MM, Lesse AJ, Sethi S, Cai X, Murphy TF (2006) Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease. Infect Immun 74(6):3366\u20133374","journal-title":"Infect Immun"},{"issue":"9","key":"332_CR6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/01.CCM.0000178185.50422.DB","volume":"33","author":"M Ferrer","year":"2005","unstructured":"Ferrer M, Ioanas M, Arancibia F, Marco MA, de la Bellacasa JP, Torres A (2005) Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 33(9):2003\u20132009","journal-title":"Crit Care Med"},{"issue":"5","key":"332_CR7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1183\/09031936.00195608","volume":"34","author":"M Miravitlles","year":"2009","unstructured":"Miravitlles M, Mar\u00edn A, Mons\u00f3 E, Vil\u00e0 S, de la Roza C, Herv\u00e1s R, Esquinas C, Garc\u00eda M, Millares L, Morera J, Torres A (2009) Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir\u00a0J 34(5):1066\u20131071","journal-title":"Eur Respir J"},{"key":"332_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","volume":"11","author":"S Sethi","year":"2010","unstructured":"Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R, PULSE Study group (2010) Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a\u00a0randomized controlled trial. Respir Res 11:10","journal-title":"Respir Res"},{"key":"332_CR9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC et\u00a0al (2011) Azithromycin for prevention of exacerbations of COPD. N\u00a0Engl J Med 365:689\u2013698","journal-title":"N Engl J Med"},{"issue":"5","key":"332_CR10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","volume":"2","author":"S Uzun","year":"2014","unstructured":"Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van\u2019t Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM (2014) Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2(5):361\u2013368","journal-title":"Lancet Respir Med"},{"key":"332_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007716.pub4","author":"X Lin","year":"2015","unstructured":"Lin X, Lu J, Yang M, Dong BR, Wu HM (2015) Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD007716.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"332_CR12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10096-015-2347-4","volume":"34","author":"N Principi","year":"2015","unstructured":"Principi N, Blasi F, Esposito S (2015) Azithromycin use in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 34(6):1071\u20131079","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"332_CR13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12879-015-0872-5","volume":"15","author":"LC Fan","year":"2015","unstructured":"Fan LC, Lu HW, Wei P, Ji XB, Liang S, Xu JF (2015) Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a\u00a0meta-analysis of randomized controlled trials. BMC Infect Dis 15:160","journal-title":"BMC Infect Dis"},{"issue":"2","key":"332_CR14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","volume":"143","author":"MJ Parnham","year":"2014","unstructured":"Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R (2014) Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 143(2):225\u2013245","journal-title":"Pharmacol Ther"},{"issue":"12","key":"332_CR15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","volume":"189","author":"MK Han","year":"2014","unstructured":"Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJ (2014) Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 189(12):1503\u20131508","journal-title":"Am J Respir Crit Care Med"},{"key":"332_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00081-2015","author":"JD Chalmers","year":"2016","unstructured":"Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, Murris-Espin M, Masefield S, Gerada E, Shteinberg M, Ringshausen F, Haworth C, Boersma W, Rademacher J, Hill AT, Aksamit T, O\u2019Donnell A, Morgan L, Milenkovic B, Tramma L, Neves J, Menendez R, Paggiaro P, Botnaru V, Skrgat S, Wilson R, Goeminne P, De Soyza A, Welte T, Torres A, Elborn JS, Blasi F (2016) The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. \n                        https:\/\/doi.org\/10.1183\/23120541.00081-2015","journal-title":"ERJ Open Res"},{"issue":"7","key":"332_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-0034-1392254","volume":"69","author":"J Rademacher","year":"2015","unstructured":"Rademacher J, de Roux A, Ringshausen FC (2015) PROGNOSIS\u2014The PROspective German NOn-CF BronchiectaSIS Patient Registry. Pneumologie 69(7):391\u2013393","journal-title":"Pneumologie"},{"key":"332_CR18","doi-asserted-by":"crossref","unstructured":"Polverino E et\u00a0al (2017) European Respiratory Society (ERS) guidelines for the management of adult bronchiectasis. Eur Respir\u00a0J 50(3)","DOI":"10.1183\/13993003.00629-2017"},{"key":"332_CR19","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s00108-010-2716-0","volume":"51","author":"J Rademacher","year":"2010","unstructured":"Rademacher J, Pletz MW, Welte T (2010) Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis). Internist (Berl) 51:1510\u20131515","journal-title":"Internist (Berl)"},{"issue":"4","key":"332_CR20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","volume":"47","author":"S Aliberti","year":"2016","unstructured":"Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Fardon TC, Rutherford R, Pesci A, Restrepo MI, Sotgiu G, Chalmers JD (2016) Clinical phenotypes in adult patients with bronchiectasis. Eur Respir\u00a0J 47(4):1113\u20131122","journal-title":"Eur Respir J"},{"key":"332_CR21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","volume":"183","author":"MP Murray","year":"2011","unstructured":"Murray MP, Govan JR, Doherty CJ et al (2011) A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 183:491\u2013499","journal-title":"Am J Respir Crit Care Med"},{"key":"332_CR22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","volume":"41","author":"R Wilson","year":"2013","unstructured":"Wilson R, Welte T, Polverino E et al (2013) Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a\u00a0phase II randomised study. Eur Respir\u00a0J 41:1107\u20131115","journal-title":"Eur Respir J"},{"issue":"9","key":"332_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","volume":"68","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Bilton D, De Soyza A et al (2013) Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a\u00a0randomised, double-blind, placebo-controlled trial. Thorax 68(9):812. \n                        https:\/\/doi.org\/10.1136\/thoraxjnl-2013-203207","journal-title":"Thorax"},{"key":"332_CR24","first-page":"56","volume-title":"Inhaled liposomal ciprofloxacin in patients with Bronchiectasis and chronic pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and ORBIT-4) . Abstract book","author":"C Haworth","year":"2017","unstructured":"Haworth C (2017) Inhaled liposomal ciprofloxacin in patients with Bronchiectasis and chronic pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and ORBIT-4) . Abstract book. 2nd World Bronchiectasis Conference, Milano, S 56"},{"issue":"2","key":"332_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","volume":"44","author":"AM Brodt","year":"2014","unstructured":"Brodt AM, Stovold E, Zhang L (2014) Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a\u00a0systematic review. Eur Respir\u00a0J 44(2):382\u2013393","journal-title":"Eur Respir J"},{"issue":"17","key":"332_CR26","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S Denus de","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL (2017) Spironolactone metabolites in TOPCAT\u2014new insights into regional variation. N\u00a0Engl J Med 376(17):1690\u20131692","journal-title":"N Engl J Med"},{"key":"332_CR27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N et al (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 380:660\u2013667","journal-title":"Lancet"},{"key":"332_CR28","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg J, de Graaff CS, Stienstra Y et al (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309:1251\u20131259","journal-title":"JAMA"},{"key":"332_CR29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","volume":"309","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Martin ML, McGuckin MA et al (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309:1260\u20131267","journal-title":"JAMA"},{"issue":"12","key":"332_CR30","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","volume":"2","author":"GB Rogers","year":"2014","unstructured":"Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ (2014) The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2(12):988\u2013996","journal-title":"Lancet Respir Med"},{"issue":"4","key":"332_CR31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201502-0223OC","volume":"192","author":"MA Sze","year":"2015","unstructured":"Sze MA, Dimitriu PA, Suzuki M, McDonough JE, Campbell JD, Brothers JF, Erb-Downward JR, Huffnagle GB, Hayashi S, Elliott WM, Cooper J, Sin DD, Lenburg ME, Spira A, Mohn WW, Hogg JC (2015) Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192(4):438\u2013445","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"332_CR32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MCP.0000000000000032","volume":"20","author":"A Mohan","year":"2014","unstructured":"Mohan A, Sethi S (2014) The reliability and validity of patient-reported chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 20(2):146\u2013152","journal-title":"Curr Opin Pulm Med"},{"key":"332_CR33","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K et\u00a0al (2012) Azithromycin and the risk of cardiovascular death. N\u00a0Engl J Med 366:1881\u20131890","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0332-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T10:57:41Z","timestamp":1508929061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0332-y"}},"subtitle":["Stellenwert der Antibiotikadauertherapie","Role of long-term antibiotic treatment"],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0332-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}